- Home
- STEP vs TERN Comparison
STEP vs TERN Comparison
Compare STEP & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEP | TERN |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.8B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STEP | TERN |
|---|---|---|
| Price | $44.80 | $53.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $76.14 | $47.38 |
| AVG Volume (30 Days) | 1.2M | ★ 5.3M |
| Earning Date | 02-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.24% | N/A |
| EPS Growth | N/A | ★ 11.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,174,830,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $30.63 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 65.09 | N/A |
| 52 Week Low | $40.27 | $1.87 |
| 52 Week High | $77.80 | $53.19 |
Technical Indicators
Market Signals| Indicator | STEP | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 37.67 | 77.08 |
| Support Level | $40.58 | $38.99 |
| Resistance Level | $63.60 | N/A |
| Average True Range (ATR) | 1.80 | 1.99 |
| MACD | 0.73 | 0.52 |
| Stochastic Oscillator | 29.67 | 98.27 |
Price Performance
Historical ComparisonAbout STEP StepStone Group Inc.
StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.